TABLE 5.

Cost effectiveness of palivizumab in Canadian subpopulations

Infant category	Direct costs ICER/QALY, $CAN
32 to 35 weeks’ GA – including asthma	20,924
32 to 35 weeks’ GA – excluding asthma	30,618
Moderate risk (RST* score 49 to 64)	34,215
High risk (RST* score 65 to 100)	5,765
<6 months (<1 year) on Baffin Island (Nunavut)	10,190 (39,435)
<6 months (<1 year) in Iqaluit (Nunavut)	103,325 (152,145)
<6 months (<1 year) in rural regions	Dominant = cost savings (24,750)

Adapted from references 102 and 118. Decision thresholds for adoption of Canadian interventions (139).

^*RST Risk scoring tool (see Table 2). Cost per Quality adjusted life-years (QALY): $0 to $20,000 – strong evidence; >$20,000 to $100,000 – moderate evidence; >$100,000 – weak evidence. GA Gestational age; ICER Incremental cost-effective ratio